Hims & Hers to acquire European telehealth platform in global expansion

Hims & Hers Health is set to acquire European telehealth platform Zava to accelerate its global expansion, adding 1.3 million active customers and extending its reach to Ireland, France, and Germany. The acquisition, expected to close by mid-year, will increase Hims & Hers' active customer base by approximately 50% and leverage Europe's more competitive pharmaceutical pricing. Zava's platform will initially retain its branding before transitioning to Hims & Hers, with Zava's CEO becoming a general manager of the international business.

Analysis

Hims & Hers Health (HIMS) is strategically accelerating its global expansion through the definitive agreement to acquire European telehealth platform Zava, a transaction expected to close by mid-year. This acquisition is poised to significantly scale Hims & Hers' operations, increasing its active customer base by approximately 50% by adding Zava's 1.3 million customers to its existing 2.4 million subscribers. The deal will also extend the company's geographic reach into key European markets including Ireland, France, and Germany, building upon its initial international foray into the United Kingdom with the 2021 acquisition of Honest Health. Hims & Hers' CEO, Andrew Dudum, highlighted the more consumer-advantageous pharmaceutical pricing in Europe as a key factor, suggesting that providing accessible treatments overseas could be as, or more, efficient than in the U.S. market. Zava's CEO, David Meinertz, who will become general manager of the international business, noted the substantial demand in Europe and telehealth's role in alleviating pressure on statutory healthcare systems. While specific financial terms of the Zava acquisition were not disclosed, they will be detailed in financial disclosures at closing. Zava's platform will maintain its branding for a transitional period before being rebranded as Hims & Hers, indicating a phased integration approach. This move underscores Hims & Hers' confidence in its growth trajectory, even amidst broader macroeconomic uncertainty where other companies may be retracting.

Key Decisions for Investors

• Investors should view this acquisition as a significant catalyst for Hims & Hers' top-line growth and market penetration in Europe, driven by a substantial increase in customer base and entry into new large markets.
• It is critical to monitor the financial disclosures upon deal closure to assess the valuation multiples, funding mechanisms, and potential impact on Hims & Hers' financial statements and future profitability.
• Consider the execution risk associated with integrating Zava and realizing synergies, but also note the potential upside from leveraging Europe's more favorable pharmaceutical pricing environment and established demand.
• Evaluate Hims & Hers' aggressive international expansion strategy in the context of the current macroeconomic climate; successful execution could differentiate the company, while potential challenges in new markets or integration complexities should be considered.